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INHERITED BONE MARROW FAILURE SYNDROMES
James Joseph Southern Maine Community College, Spring 2021
The inherited bone marrow failure syndromes are heterogeneous group of rare genetic
disorders characterized by bone marrow failure, congenital anomalies, and cancer
predisposition. This includes disorders associated with pancytopenia, such as fanconi
anemia and dyskeratosis congenita, as well as disorders with predominantly, but not
exclusively, single lineage cytopenias.
These syndromes are associated with mutations in 33 genes, and this has led to further
understanding of hematopoiesis and how this is disrupted in patients with bone marrow
failure. Other fundamental biological pathways were examined in patients, such as the
DNA repair-fa/BRCA pathway. Fanconi anemia/BRCA is a human tumor suppressor gene
also known as a caretaker gene and is responsible for repairing damage DNA or destroy
cells if DNA cannot be repaired. Another pathway examined was the telomere
maintenance of dyskeratosis congenita, an inherited bone marrow failure syndrome
characterized clinically by the triad of abnormal nails, reticular skin pigmentation, that has
been found to have x-linked recessive, autosomal dominant and autosomal recessive
subtypes. There is also a mutated gene in x-linked DC (DKC1) which encodes a highly
conserved nucleolar protein called dyskerin. Dyskerin associates with the H/ACA (human
anti-chimeric antibody) a class of small nucleolar RNA in small nucleolar
ribonucleoprotein particles (snornp), which are important in guiding the conversion of
uracil to pseudouracil during the maturation of ribosomal RNA.
This poster will review recent literature about the mutations that are most directly
associated with this rare genetic disorder.
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Interconnected pathways that cause bone 
marrow failure
Genes known to be mutated in the different pathways that lead to bone marrow failure are 
highlighted in the interconnected pathways. Genes mutated in the telomere maintenance pathway 
are circled in purple. The mutated gene and other interconnecting proteins are: RP ribosomal 
protein; FANC, Fanconi anemia complementation group; DKC1, dyskeratosis congenita 1, 
dyskerin; NOP10, nucleolar protein 10 homolog; NHP2, non-histone ribonucleoprotein 2 
homolog; GAR1, glycine and arginine rich riboncleoprotein 1 homolog; TERF1, telomeric 
repeat binding factor 1; TERF2, telomeric repeat binding factor 2; TINF2, TERF1-interacting 
nuclear factor 2; TERF2IP, TERF2 interacting protein (RAP1); POT1 protection of telomeres 1 
homolog; TPP1, TIN2 interacting protein 1 (ACD, adrenocortical dysplasia homolog); PINX1, 
PIN2 (TERF1) interacting protein; ATM, ataxia telangiectasia mutated; M/R/N: 
MRE11/RAD50/NBS1, meiotic recombination 11 homolog A/radiation resistance 50 
homolog/Nijmegen breakage syndrome 1; ATR, ataxia telangiectasia and Rad3 related (Seckel 
syndrome); BRCA1, breast cancer 1. BRIP1, BRCA1 interacting protein C-terminal helicase 1; 
PALB2, partner and localizer of BRCA2.
Dr. Daniel Moore, Samantha Bergerone, Erica Mallory, Anastasiya Popova Classmates 
(Southern Maine Community College, University of Southern Maine)… 
Bone marrow failure (BMF) disorders are characterized by presentation with pancytopenia 
or single lineage cytopenias. Although acquired aplastic anemia (AA) is the most common 
BMF disease at all ages, children and adults may have an inherited BMF (IBMF) disease 
that must be diagnosed if present, because this is critically important not only for treatment 
choices but also to monitor for progression to myelodysplastic syndrome (MDS) or acute 
myeloid leukemia (AML). MDS and AML occur with increased frequency through 
acquisition of somatic mutations in medically treated patients with acquired AA but have a 
much greater likelihood in patients with germline.
This reviewed article presents the cases of pancytopenia associated with acquired aplastic 
anemia and bone marrow failure syndromes. These disorders has been differentiated for the 
presentation of treatment decisions. Identification of new inherited germline cell diseases 
as a result of genetic testing intervention in patients presented with inherited bone marrow 
failure disorder was made possible. In patients, evidence as shown that many individuals 
with this disorder may appear to be normal with fewer or no symptoms in clinical settings. 
The prognostic value of somatic mutation may vary in different stages of individual level 
of advancement of the disease. The proliferative defect observed in inherited bone marrow 
failure syndrome can be reversed using hematopoietic stem cells, which may still furtherly 
develop somatic mutations and may progress to myelodysplastic syndrome or acute 
myeloid leukemia.
Fig.1. Image adapted from Hematol Oncol Clin North Am. 2018 Aug; 32(4): 643–655.
Fig.3 Image adapted from Hematol Oncol Clin North Am. 2018 Aug; 32(4): 643–655.
Fig.4. Image adapted from Ferrata Storti Foundation
Fig.2. Image adapted from Hematol Oncol Clin North Am. 2018 Aug; 32(4): 643–655.
The Image above fig. depicts the pathways affected in inherited bone 
marrow failure and MDS/AML predisposition syndromes. The abnormal 
chromosomal breakage, if present mutation are seen in one of the genes 14.
This also shows presence of a mutation in the DCK1, TERT or TERC genes 
16, by increased erythrocyte adenosine deaminase (eada) activity and/or by 
mutation in the RPS19, RPS24, RPS17, RPL5, RPL11 or RPL35A genes 
18. Presence of neutropenia associated with exocrine pancreatic 
insufficiency and, if possible, by mutation in the SBDS gene 6.
An onset of thrombocytopenia, typical bone marrow findings, and 
mutations in the thrombopoietin receptor (cmpl) gene 7.
In AA, number of tests demonstrated that untreated AA leads to the
apoptosis of CD3+, inhibits CD34+ cell which is crucial for HSPCs
Immune mediated selection pressure drives the expansion of HSPCs 
(Hematopoietic stem and progenitor cells) with context to specific growth 
advantage.
Bone marrow failure syndromes are associated with dysfunctional hematopoiesis that may 
drive a strong selective pressure that favors mutated hematopoietic stem and progenitor cells 
with enhanced fitness. as seen in the fig. above (red) some mutations may result in leukemic 
transformation, others may enable clonal expansion due to functional complementation of 
disease specificity to cellular defects (green). The latter may involve biological pathways that 
are distinct from leukemic transformation and not associated with elevated risk of progression 
to MDS or AML.
Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome characterized clinically by the 
triad of abnormal nails, reticular skin pigmentation, and oral leukoplakia, and associated with very high 
risks of developing aplastic anemia, myelodysplastic syndrome, leukemia, and solid tumors. Patients have 
very short germline telomeres, and approximately half have mutations in one of six genes encoding proteins 
that maintain telomere function.
Severe congenital neutropenia is characterized by profound peripheral neutropenia. Individual with the congenital 
disorder usually present with recurrent, life-threatening infections in infancy. Bone marrow examination usually 
reveals a maturation arrest in the myeloid lineage. The disease can progress to myelodysplasia and leukemia, usually 
with acquisition of secondary mutations including mutations in the granulocyte colony-stimulating factor receptor. 
Heterozygous mutations in the neutrophil elastase gene (ELA2) have been demonstrated in the majority of patients.
These mutations are thought to lead to the accumulation of a non-functional protein which in turn triggers an 
unfolded protein response leading to maturational arrest. The original family described by Kostmann, had autosomal 
recessive severe congenital neutropenia, which has been shown to be associated with biallelic mutations in 
the HAX1 gene predicted to lead to defects in cell death. Mutations in other genes (GFI1, WASP) are also known to be 
associated with severe congenital neutropenia, demonstrating genetic heterogeneity
Fanconi anemia is a rare but serious blood disorder that prevents bone marrow from making enough new 
blood cells for body to perform normal functional activities. It can cause to bone marrow (the sponge-like 
tissue in the bones), to make abnormal blood cells. It is an inherited autosomal recessive caused by 
mutation in the genes known as the FA genes, which provides instruction to repair certain types of DNA 
damage.
Myelodysplastic syndrome (MDS) is one of a group of cancers in which immature blood cells in the bone 
marrow do not mature, cannot form healthy blood cells. 
Lastly, numbers of evidence shows that individual presented with bone marrow failure 
were suspected to have inherited bone marrow failure by the combination of  various 
factors observed at young age, low birth weight, macrocytosis and high levels of 
hemoglobin F. However, most individual shows a normal chromosomal breakage test, 
normal telomere length, and no mutations in SBDS or c-mpl genes. Furthermore, The 
BRCA1/2 majorly play a huge role in the regulation of telomere maintenance and a 
mutation in this gene may result in BMFS, in addition, there are still some ongoing 
research been tested.
